{
    "2021-09-02": [
        [
            {
                "time": "",
                "original_text": "财信证券维持大参林推荐评级：新冠疫情影响+费用增加，拖累2021Q2业绩表现，目标价67.60-76.05元 盈利能力下降",
                "features": {
                    "keywords": [
                        "大参林",
                        "新冠疫情影响",
                        "费用增加",
                        "2021Q2业绩表现",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}